Nurix Therapeutics Extends Ongoing Research Program With Sanofi For STAT6; Anticipates Nominating A Clinical Candidate Within The First Year Of Extension

Author: Benzinga Newsdesk | April 09, 2024 07:01am

STAT6 is a key drug target in type 2 inflammation. Upon signing the agreement in December 2019, Sanofi made an upfront payment of $55 million and subsequently paid an additional $22 million one year later to expand the scope of the collaboration. Under the agreement, Nurix remains eligible for up to a total of $2.5 billion in potential future milestones as well as royalties on future products. With today's announcement, Nurix and Sanofi have agreed to extend the research term for the ongoing STAT6 program with the goal of nominating a development candidate in the first year of the extended term.

Posted In: NRIX SNY